Tirzepatide
The dual-agonist that redefined metabolic regulation.
Includes syringes & alcohol pads
HPLC-verified ≥99% purity · Certificate of Analysis
Two receptors working in concert.
Tirzepatide activates both GLP-1 and GIP receptors — a dual mechanism that expanded what metabolic peptides can do. GLP-1 regulates satiety and insulin release. GIP contributes a complementary signal that refines glycemic control and influences fat metabolism.
The molecule that the medical world now knows by its brand names was not an accident. It is one of the most studied metabolic peptides of the past decade, and its effects on appetite, body composition, and glucose handling are well-characterized.
Satiety Signaling
GLP-1 engagement reduces appetite and supports adherence.
Glycemic Control
Glucose-dependent insulin release without the hypoglycemia risk of older agents.
Fat Metabolism
Researched for effects on visceral and subcutaneous adiposity.
Slow GI Transit
Delayed gastric emptying that reinforces satiety between meals.
Background
Tirzepatide is one of the most studied metabolic peptides of the past decade. Its dual GLP-1 and GIP activity has been extensively characterized in the research literature.
Often paired with:
Questions, answered.
"The signal every cell recognizes. The conversation metabolism was waiting to have."
Retatrutide
Three receptors. One molecule. A new conversation with metabolism.
NAD+
The current beneath every cellular conversation.
MOTS-C
The signal your mitochondria send to the rest of you.
For research use only. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.
Research peptides are short chains of amino acids used exclusively for scientific research and laboratory studies. They are not intended for human consumption, diagnostic, or therapeutic use.